Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial

被引：0
|
作者：
Anna E. C. Stoelinga
Maarten E. Tushuizen
Wilbert B. van den Hout
Mar D. M. Rodriguez Girondo
Elsemieke S. de Vries
Amar D. Levens
Dirk-Jan A. R. Moes
Tom J. G. Gevers
Suzanne van der Meer
Hans T. Brouwer
Hendrik J. M. de Jonge
Ynte S. de Boer
Ulrich H. W. Beuers
Adriaan J. van der Meer
Aad P. van den Berg
Maureen M. J. Guichelaar
Joost P. H. Drenth
Bart van Hoek
机构：
[1] Leiden University Medical Center,Department of Gastroenterology and Hepatology
[2] Leiden University Medical Center,Department of Biomedical Data Sciences
[3] Isala Hospital,Department of Gastroenterology and Hepatology
[4] Leiden University Medical Center,Department of Clinical Pharmacy and Toxicology
[5] Maastricht University Medical Center,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[6] European Reference Network RARE-LIVER,Department of Gastroenterology and Hepatology
[7] University Medical Center Utrecht,Department of Gastroenterology and Hepatology
[8] Reinier de Graaf Gasthuis,Department of Gastroenterology and Hepatology
[9] Jeroen Bosch Hospital,Department of Gastroenterology and Hepatology
[10] Amsterdam University Medical Centre,Department of Gastroenterology and Hepatology
[11] Location VU University Medical Center,Department of Gastroenterology and Hepatology
[12] Amsterdam University Medical Centre,Department of Gastroenterology and Hepatology
[13] Location Academic Medical Center,Department of Gastroenterology and Hepatology
[14] Erasmus University Medical Center,Department of Gastroenterology and Hepatology
[15] University Medical Center Groningen,Department of Gastroenterology and Hepatology
[16] Medisch Spectrum Twente,Department of Gastroenterology and Hepatology
[17] Radboud University Medical Center,Department of Gastroenterology and Hepatology
[18] Elisabeth Tweesteden Hospital,Department of Gastroenterology and Hepatology
[19] Rijnstate Hospital,undefined
[20] Haaglanden Medical Center,undefined
[21] Rode Kruis Hospital,undefined
来源：
Trials | / 25卷
关键词：
AIH; Autoimmune hepatitis; Autoimmune liver disease; Tacrolimus; Mycophenolate mofetil; Randomised controlled trials; Second-line treatment; Complete biochemical response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial
    Lee, I. Russel
    Tong, Steven Y. C.
    Davis, Joshua S.
    Paterson, David L.
    Syed-Omar, Sharifah F.
    Peck, Kwong Ran
    Chung, Doo Ryeon
    Cooke, Graham S.
    Libau, Eshele Anak
    Rahman, Siti-Nabilah B. A.
    Gandhi, Mihir P.
    Shi, Luming
    Zheng, Shuwei
    Chaung, Jenna
    Tan, Seow Yen
    Kalimuddin, Shirin
    Archuleta, Sophia
    Lye, David C.
    TRIALS, 2022, 23 (01)
  • [22] Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial
    I. Russel Lee
    Steven Y. C. Tong
    Joshua S. Davis
    David L. Paterson
    Sharifah F. Syed-Omar
    Kwong Ran Peck
    Doo Ryeon Chung
    Graham S. Cooke
    Eshele Anak Libau
    Siti-Nabilah B. A. Rahman
    Mihir P. Gandhi
    Luming Shi
    Shuwei Zheng
    Jenna Chaung
    Seow Yen Tan
    Shirin Kalimuddin
    Sophia Archuleta
    David C. Lye
    Trials, 23
  • [23] Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
    Zhou, T.
    Yang, Y.
    Ma, S.
    Lin, L.
    Zhou, T.
    Zhang, C.
    Ding, X.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    Huang, Y.
    Zhang, L.
    ESMO OPEN, 2021, 6 (06)
  • [24] Eribulin versus Dacarbazine in Previously Treated Patients with Advanced Liposarcoma or Leiomyosarcoma: a Randomised, Open-Label, Multicentre, Phase III Trial
    Ajgal, Z.
    Boudou-Rouquette, P.
    ONCOLOGIE, 2016, 18 (9-10) : 562 - 564
  • [25] TAILORED VERSUS BISMUTH QUADRUPLE VERSUS CONCOMITANT THERAPY FOR THE FIRST-LINE TREATMENT OF HELICOBACTER PYLORI IN CHINESE PATIENTS: A MULTICENTRE, OPEN-LABEL, RANDOMIZED CONTROL TRIAL
    Zhou, L.
    Song, Z.
    Zhang, J.
    Qian, J.
    Li, Y.
    Bai, P.
    Wang, Y.
    Xue, Y.
    HELICOBACTER, 2014, 19 : 80 - 80
  • [26] Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
    Bi, Feng
    Qin, Shukui
    Gu, Shanzhi
    Bai, Yuxian
    Chen, Zhendong
    Wang, Zishu
    Ying, Jieer
    Lu, Yinying
    Meng, Zhiqiang
    Pan, Hongming
    Yang, Ping
    Zhang, Helong
    Chen, Xi
    Xu, Aibing
    Liu, Xiufeng
    Meng, Qiu
    Wu, Liqing
    Chen, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
    Kadono, Yoshifumi
    Konaka, Hiroyuki
    Izumi, Kouji
    Anai, Satoshi
    Fujimoto, Kiyohide
    Ishibashi, Kei
    Kawai, Noriyasu
    Kato, Taku
    Iba, Akinori
    Masumori, Naoya
    Yoshimura, Kenichi
    Mizokami, Atsushiu
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 15
  • [28] Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
    Papamichael, Konstantinos
    Jairath, Vipul
    Zou, Guangyong
    Cohen, Benjamin
    Ritter, Timothy
    Sands, Bruce
    Siegel, Corey
    Valentine, John
    Smith, Michelle
    Vande Casteele, Niels
    Dubinsky, Marla
    Cheifetz, Adam
    BMJ OPEN, 2022, 12 (04):
  • [29] Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
    Liou, Jyh-Ming
    Fang, Yu-Jen
    Chen, Chieh-Chang
    Bair, Ming-Jong
    Chang, Chi-Yang
    Lee, Yi-Chia
    Chen, Mei-Jyh
    Chen, Chien-Chuan
    Tseng, Cheng-Hao
    Hsu, Yao-Chun
    Lee, Ji-Yuh
    Yang, Tsung-Hua
    Luo, Jiing-Chyuan
    Chang, Chun-Chao
    Chen, Chi-Yi
    Chen, Po-Yueh
    Shun, Chia-Tung
    Hsu, Wen-Feng
    Hu, Wen-Hao
    Chen, Yen-Nien
    Sheu, Bor-Shyang
    Lin, Jaw-Town
    Wu, Jeng-Yih
    El-Omar, Emad M.
    Wu, Ming-Shiang
    LANCET, 2016, 388 (10058): : 2355 - 2365
  • [30] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
    Baas, Paul
    Scherpereel, Arnaud
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Jahan, Thierry
    Antonia, Scott
    Oulkhouir, Youssef
    Bautista, Yolanda
    Cornelissen, Robin
    Greillier, Laurent
    Grossi, Francesco
    Kowalski, Dariusz
    Rodriguez-Cid, Jeronimo
    Aanur, Praveen
    Oukessou, Abderrahim
    Baudelet, Christine
    Zalcman, Gerard
    LANCET, 2021, 397 (10272): : 375 - 386
12345